Antiarrhythmic and cardiac electrophysiological effects of SZV-270, a novel compound with combined Class I/B and Class III effects, in rabbits and dogs

Cardiovascular diseases are the leading causes of mortality. Sudden cardiac death is most commonly caused by ventricular fibrillation (VF). Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of stroke and heart failure. Pharmacological management of VF and AF...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Varga Richárd Sándor
Hornyik Tibor
Husti Zoltán
Kohajda Zsófia
Krajsovszky Gábor
Nagy Norbert
Jost Norbert László
Virág László
Tálosi László
Mátyus Péter
Varró András
Baczkó István
Dokumentumtípus: Cikk
Megjelent: 2021
Sorozat:CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 99 No. 1
doi:10.1139/cjpp-2020-0412

mtmt:31845012
Online Access:http://publicatio.bibl.u-szeged.hu/20263
LEADER 02676nab a2200337 i 4500
001 publ20263
005 20210311154559.0
008 210118s2021 hu o 0|| zxx d
022 |a 0008-4212 
024 7 |a 10.1139/cjpp-2020-0412  |2 doi 
024 7 |a 31845012  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a zxx 
100 1 |a Varga Richárd Sándor 
245 1 0 |a Antiarrhythmic and cardiac electrophysiological effects of SZV-270, a novel compound with combined Class I/B and Class III effects, in rabbits and dogs  |h [elektronikus dokumentum] /  |c  Varga Richárd Sándor 
260 |c 2021 
300 |a 89-101 
490 0 |a CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY  |v 99 No. 1 
520 3 |a Cardiovascular diseases are the leading causes of mortality. Sudden cardiac death is most commonly caused by ventricular fibrillation (VF). Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of stroke and heart failure. Pharmacological management of VF and AF remains suboptimal due to limited efficacy of antiarrhythmic drugs and their ventricular proarrhythmic adverse effects. In this study, the antiarrhythmic and cardiac cellular electrophysiological effects of SZV-270, a novel compound, were investigated in rabbit and canine models. SZV-270 significantly reduced the incidence of VF in rabbits subjected to coronary artery occlusion/reperfusion, reduced the incidence of burst-induced AF in a tachypaced conscious canine model of AF. SZV-270 prolonged frequency corrected QT interval, lengthened action potential duration and effective refractory period in ventricular and atrial preparations and blocked IKr in isolated cardiomyocytes (Class III effects), reduced maximum rate of depolarization (Vmax) at cycle lengths smaller than 1000 ms in ventricular preparations (Class I/B effect). Importantly, SZV-270 did not provoke Torsades de Pointes arrhythmia in an anesthetized rabbit proarrhythmia model characterized by impaired repolarization reserve. In conclusion, SZV-270 with its combined Class I/B and III effects can prevent re-entry arrhythmias with reduced risk of provoking drug-induced Torsades de Pointes. 
700 0 1 |a Hornyik Tibor  |e aut 
700 0 1 |a Husti Zoltán  |e aut 
700 0 1 |a Kohajda Zsófia  |e aut 
700 0 1 |a Krajsovszky Gábor  |e aut 
700 0 1 |a Nagy Norbert  |e aut 
700 0 1 |a Jost Norbert László  |e aut 
700 0 1 |a Virág László  |e aut 
700 0 1 |a Tálosi László  |e aut 
700 0 1 |a Mátyus Péter  |e aut 
700 0 1 |a Varró András  |e aut 
700 0 1 |a Baczkó István  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/20263/1/VargaBaczkoCJPP2021.pdf  |z Dokumentum-elérés